Halaven (Page 7 of 7)
PRINCIPAL DISPLAY PANEL
NDC 62856-389-01
Halaven™
(eribulin mesylate) Injection
1 mg/2 mL
(0.5 mg/mL)For Intravenous Use
PRINCIPAL DISPLAY PANEL
NDC 62856-389-01
Halaven™
(eribulin mesylate) Injection
1 mg/2 mL
(0.5 mg/mL)For Intravenous Use
HALAVEN eribulin mesylate injection | |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
|
Labeler — Eisai Inc. (189246791) |
Establishment | |||
Name | Address | ID/FEI | Operations |
BSP Pharmaceuticals SpA | 857007830 | analysis (62856-389), manufacture (62856-389) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Eisai Co., Ltd. | 695319983 | api manufacture (62856-389) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Eisai Manufacturing Ltd | 219516916 | analysis (62856-389), label (62856-389), pack (62856-389) |
Establishment | |||
Name | Address | ID/FEI | Operations |
NerPharMa S.r.l | 338839192 | analysis (62856-389), manufacture (62856-389) |
Establishment | |||
Name | Address | ID/FEI | Operations |
SAFC Inc | 605899769 | api manufacture (62856-389) |
Revised: 09/2022 Eisai Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.